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Hop-derived food supplements and beers contain the prenylflavonoids xanthohumol (X), isoxanthohumol (IX) and the very potent phyto-oestrogen
(plant-derived oestrogen mimic) 8-prenylnaringenin (8-PN). The weakly oestrogenic IX can be bioactivated via O-demethylation to 8-PN. Since
IX usually predominates over 8-PN, human subjects may be exposed to increased doses of 8-PN. A dietary intervention trial with fifty healthy post-
menopausal Caucasian women was undertaken. After a 4 d washout period, participants delivered faeces, blank urine and breath samples. Next,
they started a 5 d treatment with hop-based supplements that were administered three times per d and on the last day, a 24 h urine sample was
collected. A semi-quantitative FFQ was used to estimate fat, fibre, alcohol, caffeine and theobromine intakes. The recoveries of IX, 8-PN and
X in the urine were low and considerable inter-individual variations were observed. A five-fold increase in the dosage of IX without change
in 8-PN concentration resulted in a significant lower IX recovery and a higher 8-PN recovery. Classification of the subjects into poor (60%), mod-
erate (25%) and strong (15%) 8-PN producers based on either urinary excretion or microbial bioactivation capacity gave comparable results.
Recent antibiotic therapy seemed to affect the 8-PN production negatively. A positive trend between methane excretion and 8-PN production
was observed. Strong 8-PN producers consumed less alcohol and had a higher theobromine intake. From this study we conclude that in vivo
O-demethylation of IX increases the oestrogenic potency of hop-derived products.
Phyto-oestrogens: Hops: 8-Prenylnaringenin: Post-menopausal women
Phyto-oestrogens are polyphenolic, non-steroidal plant-derived
compounds, which are structurally related to 17b-oestradiol1.
Predominant phyto-oestrogens in the Western diet belong to
the subclasses of isoflavones, lignans and prenylflavonoids2.
Depending on the endogenous oestrogen levels and the target
tissue, these compounds can mimic or modulate the activity of
circulating oestrogens resulting in potential health effects3.
Binding of phyto-oestrogens to the human oestrogen receptors
a and b is not the only common feature of this quite diverse
group. Their bioavailability is characterized by considerable
inter-individual variation, which is partly due to differences in
metabolism by the gut microbiota4 and the background diet5,6.
Prenylflavonoids including xanthohumol (X), isoxanthohu-
mol (IX) and 8-prenylnaringenin (8-PN), are found in hops
(Humulus lupulus L. Cannabaceae) and hop-derived products
such as beers and herbal preparations claiming sedative
effects, relief of menopausal complaints or breast enhance-
ment7,8. Whereas X and IX have no or weak oestrogenic
activity, 8-PN is substantially more oestrogenic than other
dietary phyto-oestrogens9. 8-PN is also unique in respect of
its oestrogen receptor specificity, as it binds preferably to oes-
trogen receptor-a10.
The weak phyto-oestrogen IX gained much attention
recently, since it can be O-demethylated into 8-PN in vitro
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by the human faecal microbiota11 and by mammalian
cytochrome P450 enzymes12,13. As its concentration in
hop-derived products exceeds that of 8-PN by over ten-fold14,
bioactivation of IX might increase the exposure of man to
8-PN. However, analysis of fifty-one faecal samples revealed
large inter-individual variation in the IX conversion capacity
of the human intestinal bacteria, which led to a separation of
individuals in poor, moderate and high 8-PN producers15.
Until now, this bioactivation has not been studied extensively
in vivo. Schaefer et al.16 detected 8-PN in the urine of two
men after a single dose of 10mg IX mixed into a high-alcoholic
beverage. In a small in vivo trial involving three women,
Possemiers et al.15 found a clear relationship between the in
vitro transformation potential of faecal microbial cultures and
the urinary 8-PN excretion after IX consumption.
Understanding the factors influencing the bioactivation of
IX in vivo is important to estimate the 8-PN exposure after
oral administration of hop-based products. In addition to
differences in the composition and activity of the intestinal
microbiota, dietary factors may also affect the bioavailability
of phyto-oestrogens4. Macronutrient intake can selectively
modify the growth of gut bacteria involved in the bioacti-
vation of phyto-oestrogens17 by changing the intestinal pH,
redox potential or transit time or by influencing the avail-
ability of substrates18. In particular, differences in total fat
and dietary fibre consumption have been highlighted in pre-
vious studies5,6,17,19. The purpose of the present work was:
(1) to examine the extent of inter-individual variation in urin-
ary excretion of hop-derived prenylflavonoids; (2) to assess
the prevalence of the different 8-PN producer phenotypes;
(3) to evaluate the importance of microbial activation of IX
towards 8-PN exposure; (4) to identify microbial and dietary
factors that are associated with in vivo 8-PN production.
Therefore, a dietary intervention trial with fifty healthy post-
menopausal Caucasian women was conducted.
Materials and methods
Chemicals and reagents
The isolation of X from spent hops (i.e. the vegetative residue
left after liquid or supercritical CO2 extraction of hop cones;
NATECO2, Wolnzach, Germany), isomerization of X into
IX and preparation of 8-PN were performed as described by
Possemiers et al.11. A stock solution of 15mM-IX in absolute
ethanol was prepared. 4-Hydroxybenzophenone (internal stan-
dard) was obtained from Fluka Chemie (Buchs, Switzerland).
TypeH-1Helix pomatia extract (min. 300Ub-glucuronidase/mg
and 15·3U sulfatase/mg), p-nitrophenol, p-nitrophenyl-
b-D-glucopyranoside and p-nitrophenyl-b-D-glucuronide
were obtained from Sigma Aldrich (Bornem, Belgium). All
solvents were purchased from Biosolve (Valkenswaard, The
Netherlands).
Study design and population
An intervention trial with fifty healthy post-menopausal
Caucasian women was undertaken to study the microbial
metabolism of phyto-oestrogens from hops in vivo and
in vitro. Women were eligible for participation if they were
not using any exogenous hormone medications, not suffering
from a gastrointestinal disease and free of cancers. Women
who were receiving an antibiotic therapy (n 2) were scheduled
at least 1month after antibiotic therapy completion. Subject
information such as date of birth, weight, height, use of pre-,
pro-, syn- or antibiotics, smoking and time of last vaginal
bleeding were collected upon recruitment.
Participants consumed their habitual Western-type diets, but
were asked to abstain from products based on hops during the
trial. A list of prenylflavonoid-containing foods was distribu-
ted in order to help the volunteers. After a 4 d washout
period, subjects delivered a faecal sample for incubation pur-
poses and microbiological phenotyping, a blank urine sample
and two end-expiratory breath samples. Subsequently, three
hop-derived dietary supplements per d were administered
during five consecutive days and on the fifth treatment day a
24 h urine sample was collected. A self-administered semi-
quantitative FFQ was developed to estimate the usual fat,
fibre, alcohol, caffeine and theobromine consumption. This
FFQ included questions on the average consumption (fre-
quency, daily portion size) of seventy-six food items during
the past year and some additional questions involving more
detailed information about some product groups. The in-
clusion of food items was based on knowledge from pre-
viously conducted population dietary surveys in Belgium.
The validity and reproducibility of this instrument are reported
elsewhere (Bolca et al., unpublished data).
The present study was given ethical approval by the Ethics
Committee of the Ghent University Hospital (EC UZG 2005/
022). The volunteers were fully informed on the aims of the
study and gave their written consent.
Sample collection and processing
End-expiratory breath samples were collected using the Quin-
Tron GaSampler system (Ecce Medical, Schoten, Belgium).
The alveolar air samples were analysed immediately by
GC-Flame ionisation detector (FID). The background room
air was found to contain less than 2 ppm methane. Participants
were considered to be methane producers when their breath
methane concentration exceeded 3 ppm20.
Volumes of the 24 h urine samples were measured and ali-
quots were stored at2208C. For hydrolysis of conjugated pren-
ylflavonoids, a 33 g/l solution of Type H-1 Helix pomatia
extract in sodium acetate buffer (0·1 M, pH 5) was prepared.
Unfrozen urine (15ml) was added to sodium acetate buffer
(15ml) and b-glucuronidase/arylsulfatase solution (30ml)
and the samples were mixed and incubated for 1 h at 378C.
The hydrolysed samples were spiked with 90ml internal stan-
dard (0·4 M-4-hydroxybenzophenone in ethyl acetate) before
extraction. The solid-phase extraction Bond Elutw C18 silica
columns (5ml, 500mg, Varian, St.-Katelijne-Waver, Bel-
gium) were pre-conditioned with 5ml methanol, 5ml water
and 5ml sodium acetate buffer (0·1 M, pH 5), consecutively.
After sample application, the cartridges were rinsed with
5ml water and 5ml methanol/water (2:3) and the compounds
of interest were eluted with 2ml methanol using a VacMaster
20 sample processing unit (IST, Hengoed, Mid Glamorgan,
UK). Finally, the solvent was evaporated at room temperature
under a gentle stream of N2 and the residue was dissolved in
100ml methanol, transferred into HPLC vials and stored at
2208C prior to analysis.
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Faecal suspensions were prepared by homogenizing 20 g
faeces with 100ml phosphate buffer (0·5 M, pH 7) supplemented
with 1 g/l sodium thioglycolate. Particulate material was
removed by centrifugation at 400 g for 2min. To assess the
8-PN production capacity of each faecal culture, in vitro
experiments were set up following the incubation and extraction
protocols developed by Possemiers et al.11. Aliquots of faecal
suspensions were also stored at 2808C for measurement of
bacterial b-glucosidase and b-glucuronidase activities.
Hop-derived dietary supplements
Two different batches of hop-based capsules (MenoHopw,
Biodynamics bvba, Ostend, Belgium), were used: twelve
women (24%) were given BD01 capsules; thirty-eight
women (76%) ingested BD02 capsules. Composition and
manufacturing information have been described by Heyerick
et al.8. The concentrations of prenylflavonoids were measured
by HPLC-UV after extracting 200mg of the capsules
with 10ml methanol and diluting the supernatant five
times in methanol. BD01 contained 0·23 ^ 0·01mg IX,
0·10 ^ 0·01mg 8-PN and 1·38 ^ 0·03mg X per capsule;
BD02 contained 1·20 ^ 0·04mg IX, 0·10 ^ 0·01mg 8-PN
and 2·04 ^ 0·06mg X per capsule.
Quantification of methane by GC-FID
Alveolar air samples were taken using a Pressure-Lok pre-
cision analytical syringe (Alltech Ass., Deerfield, IL, USA).
The methane concentrations were measured with a Chrompack
CP 9000 GC equipped with a flame ionization detector
(Chrompack, Middelburg, The Netherlands), based on the pro-
tocol of Boeckx et al.21. The analyses were carried out using
the following conditions: injection temperature 658C; oven
temperature 358C; detector temperature 2508C. A mixture of
50·3 (SD 1·5) ppm CH4 in Ar was used as standard gas
(L’Air Liquide, Liege, Belgium).
Quantification of prenylflavonoids by HPLC-UV
Quantitative analyses of the prenylflavonoids extracted from
the urine samples, incubation media or capsules were per-
formed by HPLC-UV using a Waters 2695 Alliance separ-
ations module (Waters, Milford, MA, USA) equipped with a
Waters 996 photodiode array detector and Waters Millenium
software v3.20 as reported by Possemiers et al.11. Detection
was done simultaneously at 295 nm (for IX, 8-PN and
4-hydroxybenzophenone) and at 370 nm (for X). Peaks were
identified by comparison of the retention times and UV spectra
with those of authentic isolated reference compounds. Con-
centrations were calculated based on peak area integration
of the analytes and the internal standard.
Measurement of faecal enzyme activity
Unfrozen faecal suspensions were centrifuged at 5000 g for
5min and diluted five times in phosphate buffer (0·5M, pH 7)22.
For the assessment of b-glucosidase and b-glucuronidase
activities, the suspensions were incubated aerobically for
30min at 378C with p-nitrophenyl-b-D-glucopyranoside
(2·5mM) or p-nitrophenyl-b-D-glucuronide (2·5mM), respectively.
Release of p-nitrophenol was recorded with a Tecan Sunrisee
absorbance reader (Tecan Benelux, Mechelen, Belgium) at
405nm before and after incubation. The absorbance of a series of
different concentrations of p-nitrophenol was used to calculate
the enzymatic activities, according to the method of Berg et al.23.
Statistical approach
All extractions and analyses were performed in triplicate means
and SD were calculated. The Statistical Package for the Social
Sciences for Windows version 12.0 (SPSS Inc., Chicago, IL,
USA) was used to carry out all statistical analyses. Unless
reported differently, a P value of 0·05 was used as threshold
for significance. Two-sided significance levels are quoted.
Tests for normality of the data and equality of the variances
were performed using the Kolmogorov–Smirnov and Levene’s
test, respectively. Comparison of normally distributed data was
performed with Student’s t test or ANOVA. The non-parametric
Mann–Whitney U and Kruskal–Wallis test were used to com-
pare means of non-normally distributed data. Partial Pearson
correlation coefficients adjusted for the type of hop treatment
were computed to measure associations between urinary
parameters.
Subjects were separated into statistically different groups
using the TwoStep cluster analysis protocol. Associations
between the producer phenotype and subject characteristics,
urinary, microbial and dietary parameters were evaluated
using nominal logistic regression with poor 8-PN producers
as reference category. Cross-classification analysis calculated
the agreement between the in vivo and in vitro data.
Results
Subject characteristics and diet
The mean age of the subjects was 57 years with a range from
46 to 74 years. Twenty women (40%) were classified as over-
weight (BMI $25 kg/m2); five (25%) of these were obese
(BMI $30 kg/m2). Four women (8%) were smokers. The
majority had not used antibiotics during the past year and con-
sumed less than one pre-, pro- or synbiotic preparation per
month (Table 1). Forty-nine good-quality FFQ (98%) were
included in the analysis. The average consumption of total
fat, SFA, MUFA, PUFA, fibre and alcohol was compared
with the guideline daily amounts for seniors proposed by the
Belgian Health Council24 (Table 2). Only 10% of the study
population reported a daily fibre intake of at least 30 g/d, as
recommended. While the Belgian Health Council advises
not to drink any alcohol on a regular basis, the Eurodiet
Table 1. Time since last antibiotic therapy and frequency of consump-
tion of pre-, pro- or synbiotic preparations, expressed as a percentage
of individuals (n 50)*
Antibiotics (%) Pre-, pro- or synbiotics (%)
#1 month 0 $once per week 14
1–3 months 4 once per week 2
3–6 months 8 2–3 times per month 2
9–12 months 10 once per month 16
$1 year 78 never or less than once per month 66
* For details of subjects and procedures, see Materials and methods.
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guideline allows up to 12 g/d24. The estimated alcohol intake
of thirty-seven participants (76%) was less than 12 g/d; thir-
teen (35%) of these reported to drink less than one alcoholic
beverage per month. Twenty-eight subjects (57%) consumed
at least two cups of regular coffee per d (223·82 (SD
61·13)mg caffeine/d), while twenty-one (43%) consumed
not more than one cup (125ml) of regular coffee per d or
drank coffee with reduced caffeine content, decaffeinated or
surrogate coffee (45·52 (SD 40·00)mg caffeine/d).
Pulmonary methane excretion
Thirty-three (66%) volunteers had methane (4·05–27·95 ppm)
in their alveolar air samples and were included in the group of
methane producers. The other participants (34%) did not
exceed the selected methane threshold in their breath (1·20–
3·00 ppm). Age, BMI, use of pre-, pro-, syn- or antibiotics,
smoking and dietary parameters (total fat, SFA, MUFA,
PUFA, fibre, alcohol, caffeine and theobromine intake) were
comparable for both methane producers and non-producers.
Urinary excretion and recovery of prenylflavonoids
IX, 8-PN and X in the 24 h urine samples were quantified as
daily excretion and percentage of the daily doses recovered
(Table 3). The inter-individual variations in urinary excretion
were eighteen-fold for IX, thirteen-fold for 8-PN and six-fold
for X between subjects of the BD01 group; between the sub-
jects of the BD02 group, the inter-individual variations were
thirty-fold for IX, forty-fold for 8-PN and twenty-seven-fold
for X. A thirteen-fold variation in the renal excretion of
total prenylflavonoids was observed in both treatment
groups. The recoveries of IX, 8-PN and X were low,
especially for X. Less than 1% of the dosed X was found in
the urine. A 1·5-fold increase in X dosage resulted in an equiv-
alent rise in urinary X excretion. In contrast, multiplying the
ingested amount of IX with a factor five decreased the recov-
ery of IX significantly (P¼0·005). Although the capsules
contained the same amount of 8-PN, the average 8-PN
excretion was higher in the BD02 group, but the difference
was statistically not significant. When controlling for the
type of hop treatment, the urinary recovery of IX correlated
modestly with the recovery of 8-PN (R 0·293; P¼0·041).
There was a stronger correlation between the recoveries of
X and IX (R 0·445; P¼0·001) and of X and 8-PN (R 0·605;
P,0·001), respectively. Neither the faecal b-glucosidase
(24·6 ^ 19·9mmol p-nitrophenol/h per g faeces) nor the
b-glucuronidase (15·5 (SD 9·9)mmol p-nitrophenol/h per g
faeces) activity correlated with the excretion of IX, 8-PN or X.
Based on the ratio 8-PN:(8-PN þ IX) excreted in the urine
and the type of hop treatment, three different groups were
formed (Fig. 1(A)). Thirty-one (62%), twelve (24%) and
seven (14%) women were classified as poor, moderate and
strong in vivo 8-PN producers, respectively. The average urin-
ary recovery of 8-PN (P¼0·014) and IX (P¼0·002) were sig-
nificantly different between these groups, while the average
recovery of X (P¼0·374) was similar.
Microbial metabolism of prenylflavonoids
The microbial metabolism of IX was highly variable ranging
from 0 up to 100% IX transformed into 8-PN and led to a
separation of the subjects in poor (61%), moderate (27%)
and strong (12%) in vitro 8-PN producers (Fig. 1(B)). These
clusters had significantly different average urinary recoveries
of 8-PN (P¼0·027) and X (P¼0·032), but not for IX. The
percentages IX transformed and 8-PN produced by the
faecal cultures correlated inversely (R 20·650, P,0·001).
The prevalence of poor, moderate and strong in vitro 8-PN
producers was not significantly influenced by the type of
hop treatment.
Table 2. Actual and guideline daily intakes and percentage of the FFQ
reports*†
(Mean values and standard deviations for forty-nine subjects)
Consumption (g/d)
Actual
Food item Mean SD Guideline Subjects (%)
Total fat 54·18 20·83 ,67 72
SFA 23·15 9·46 ,22 47
MUFA 27·00 10·40 .22 27
PUFA 9·11 3·91 12–22 25
Fibre 19·61 6·77 .30 10
Alcohol 8·46 12·11 0 27
Caffeine 0·15 0·10 US US
Theobromine 0·03 0·04 US US
* FFQ reports are in agreement with the recommendations for seniors proposed by
the Belgian Health Council24.
† For details of subjects and procedures, see Materials and methods.
US, unspecified.
Table 3. Concentrations of isoxanthohumol (IX), 8-prenylnaringenin (8-PN) and xanthohumol (X) in 24 h urine samples of post-menopausal
women who ingested a hop-based food supplement BD01 (n 12) or BD02 (n 38) three times per d for 5 d*
(Mean values and standard deviations)
Excretion (mg/d) Recovery (%)
IXa 8-PN X IXb 8-PN X
Food supplement Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
BD01 187·3 162·1 35·5 23·6 14·2 9·2 26·9 24·6 11·6 7·8 0·33 0·22
BD02 287·8 200·7 51·8 38·5 19·3 10·9 8·0 5·6 16·3 12·2 0·32 0·18
aP¼0·054, BD01 v. BD02.
bP¼0·005, BD01 v. BD02.
* For details of subjects and procedures, see Materials and methods.
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Factors associated with 8-prenylnaringenin production
Associations between the in vivo 8-PN producer phenotype
and subject characteristics, microbial and dietary parameters
are presented in Table 4. Individuals who had not taken anti-
biotics at least 6 months before participation were more likely
to be strong in vivo 8-PN producers (P¼0·035). There was
some indication (0·050 , P,0·075) that pulmonary methane
excretion was positively related with in vivo 8-PN production.
A lower reported alcohol consumption (P¼0·039) and a
higher intake of theobromine (P¼0·050) were associated
with the strong in vivo 8-PN producer phenotype.
Most of the subject characteristics, urinary, microbial and
dietary parameters were not strongly associated with the
in vitro 8-PN producer phenotype (Table 5). However, positive
trends (0·050 , P,0·075) between urinary excretion and
recovery of X and in vitro 8-PN production were observed.
Lower estimated alcohol (P¼0·041) and higher theobromine
intake (P¼0·047) correlated with the in vitro strong 8-PN
producer phenotype.
As alcohol consumption differed between the 8-PN produ-
cer phenotypes, this topic was examined more thoroughly.
Alcoholic beverages were included in four items of the
FFQ: aperitif; wine and champagne; beer; liqueurs and spirits.
In addition to the frequency and daily portion size of beer con-
sumption, questions on the type of beer (no or low alcoholic,
pilsner type or strong beer) were included to estimate the usual
intake of both alcohol and prenylflavonoids. Neither in vivo
nor in vitro 8-PN production correlated significantly with the
usual beer consumption. Twenty-six women (53%) reported
to drink less than 200ml beer per month, whereas the
others had an average estimated beer consumption of 56
(SD 70 ) ml/d. Habitual X, IX, 8-PN and total prenylflavonoid
intakes were similar in all 8-PN producer phenotypes and
ranged from 0 to 102mg/d for X, 0 to 630mg/d for IX, 0 to
21mg/d for 8-PN and 0 to 753mg/d for total prenylflavonoids.
Cross-classification analyses for 8-PN producer phenotypes
estimated from in vivo and in vitro data indicated that
six women (12·2%) were misclassified, while twenty-six
subjects (53·1%) were classified correctly and forty-three
participants (87·7%) were classified correctly or in the
adjacent category.
Discussion
The prenylflavonoids X, IX and 8-PN are found in hops
(Humulus lupulus L. Cannabaceae) and hop-derived products,
including beers and food supplements. As bioactivation of IX
to the potent phyto-oestrogen 8-PN might increase the oestro-
genic potency of such products, the metabolism of prenyl-
flavonoids was studied in vivo and in vitro. In order to work
with the target population for phyto-oestrogen therapy and to
minimize the variations in circulating oestrogen concentrations
and their possible interactions with the phyto-oestrogen
metabolism25 and liver enzymes26, only healthy hormone-
naive women were included. The recoveries of the dosed
IX, 8-PN and X were low and considerable inter-individual
variations were observed. Classification of the volunteers
into poor (60%), moderate (25%) and strong (15%) 8-PN
producers based on either urinary excretion or microbial
bioactivation capacity of faecal samples gave comparable
results. Recent antibiotic therapy seemed to affect the 8-PN
production negatively. A positive trend between methane
excretion and 8-PN production was observed. A lower alcohol
and a higher theobromine intake were associated with the
strong 8-PN producer phenotype.
Less than 1% of the administered X was excreted in the
urine and a 1·5-fold increase in X dosage resulted in an equiv-
alent rise in urinary excretion. After oral administration of 20
to 500mg/kg body weight X as a pure compound or as a hop
extract, Avula et al.27 found 0·06–0·49% of the dosed X in
the urine and more than 99·5% in the faeces of rats. These
results suggest that X is poorly absorbed through the intestinal
wall, thereby resulting in a low oral bioavailability. This fea-
ture may be an important bottleneck in the development of X
as a novel broad-spectrum cancer chemopreventive agent28.
Based on the apparent permeability coefficients assessed in
the Caco-2 cell monolayer model, Nikolic et al.29 predicted
a rather efficient intestinal absorption via passive diffusion
for 8-PN. This rapid enteral absorption was also found
after a single oral administration of 8-PN to healthy post-
menopausal women30, as well as in the present study.
The recoveries of 8-PN and IX in the 24 h urine samples
Fig. 1. Clustering of individuals (n 50) in three significantly different groups,
namely, poor, moderate and strong 8-prenylnaringenin (8-PN) producers,
based on (A) the ratio 8-PN:(8-PN þ isoxanthohumol (IX)) excreted in the
24 h urine and the type of hop treatment; (B) the capacity of the faecal micro-
biota to convert IX in 8-PN. Values are means with their standard deviations
represented by vertical bars. For details of subjects and procedures, see
Materials and methods.
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were comparable to those reported for the isoflavones genis-
tein (8–16%) and daidzein (15–50%)31–33.
The observed inter-individual variation in urinary
excretion of prenylflavonoids was considerable and higher
than the 5·5-fold variation in 24 h renal excretion of 8-PN
reported by Schaefer et al.16 in a small trial involving six
subjects. In comparison, concentrations of the isoflavones
genistein and daidzein in 24 h urine samples varied between
subjects twelve- to twenty-four-fold and thirteen to eighty-
five-fold, respectively5,32,34. Lampe et al.35 and Rowland
et al.17 reported a wider range of excretion of the microbial
daidzein metabolites equol and O-desmethylangolensin and
the enterolignans enterolacton and enterodiol in human
subjects.
The urinary recovery data indicated that the excretion of
IX and 8-PN was dependent on the ingested amount of IX.
A five-fold increase in IX dosage decreased the recovery
of IX significantly. Simultaneously, the average 8-PN
excretion increased although the ingested amount of 8-PN
was unchanged. This is probably due to the conversion of
IX into 8-PN in vivo. Urinary excretion of 8-PN after con-
sumption of IX has also been reported by Schaefer et al.16
and Possemiers et al.15, and in both studies inter-individual
differences were noticed. In addition, the urinary recovery
of 8-PN was significantly different between poor, moderate
and strong 8-PN producers. As the prevalence of the different
8-PN producer phenotypes was equivalent in both treatment
groups, these results suggest that the extent of the conversion
Table 4. Subject characteristics, microbial and dietary parameters in relation to the in vivo 8-prenylnaringenin
(8-PN) producer phenotype, expressed as OR and upper and lower 95 % CI derived from nominal logistic
regression with poor in vivo 8-PN producers as reference category*
In vivo 8-PN producer
Moderate Strong
95 % CI 95 % CI
OR Upper Lower OR Upper Lower
Subject characteristics
Age (years) 0·986 0·870 1·118 0·945 0·792 1·128
BMI (kg/m2) 1·097 0·919 1·310 0·999 0·780 1·278
Smoking
Yes 0·000 0·000 0·000 0·000 0·000 0·000
No 1·000 Reference 1·000 Reference
Use of antibiotics
1–3 months 2·500 0·142 43·97 0·000 0·000 0·000
3– 6 months 0·833 0·077 8·995 0·000 0·000 0·000
6– 12 months 0·000 0·000 0·000 9·375 1·174 74·84
$ 1 year 1·000 Reference 1·000 Reference
Microbial parameters
Pulmonary methane excretion 1·472 0·554 3·912 1·121 0·326 3·858
Enzyme activities (mmol/h per g)
b-glucuronidase 1·056 0·970 1·151 0·935 0·825 1·061
b-glucosidase 1·039 0·987 1·094 1·065 1·002 1·132
Faecal metabolism
Degradation of IX 1·033 0·990 1·079 0·989 0·946 1·034
Production of 8-PN 1·041 0·988 1·096 1·011 0·957 1·067
Dietary parameters
Fat consumption (g/d)
Total fat 1·538 0·565 4·189 0·700 0·192 2·558
SFA 0·523 0·169 1·618 1·670 0·383 7·291
Unsaturated fatty acids 0·638 0·246 1·658 1·327 0·386 4·564
MUFA 1·326 0·556 3·165 0·934 0·383 2·277
PUFA 1·042 0·878 1·236 0·926 0·726 1·180
Fat consumption (%)
SFA 0·822 0·492 1·374 1·115 0·620 2·007
Unsaturated fatty acids 0·939 0·634 1·392 0·992 0·607 1·622
Fibre consumption (g/d) 1·103 0·991 1·227 1·051 0·927 1·191
Fat:fibre ratio 0·617 0·317 1·202 0·665 0·312 1·416
Alcohol consumption (g/d) 0·799 0·350 1·821 0·257 0·071 0·933
Methylxanthine intake (mg/d)
Caffeine 1·000 0·991 1·009 0·998 0·987 1·010
Theobromine 0·757 0·395 1·451 2·041 0·793 5·255
Pre-, pro-, synbiotics
$ once per week 1·500 0·224 10·04 1·313 0·115 15·03
once per week 6·6 E8 6·6 E8 6·6 E8 1·016 1·016 1·016
2–3 times per month 0·000 0·000 0·000 0·000 0·000 0·000
once per month 1·200 0·189 7·628 1·050 0·095 11·56
# once per month 1·000 Reference 1·000 Reference
* For details of subjects and procedures, see Materials and methods.
IX, isoxanthohumol.
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depends on the IX dose administered. Cross-over studies with
different IX doses are warranted to investigate this in more
detail.
The 8-PN production was estimated from in vivo as well as
in vitro data. The study population was separated into poor
(62%), moderate (24%) and strong (14%) in vivo 8-PN pro-
ducers. Based on the microbial bioactivation capacity of the
faecal cultures, a similar classification prevailed. This is in
quite good agreement with the incubation experiments of
Possemiers et al.15, which separated faecal samples into
slow (63%), moderate (21%) and high (16%) IX converters.
The hypothesis that microbial and dietary factors give rise to
these different 8-PN producer phenotypes was tested.
The inverse relationship between use of antibiotics and
8-PN production indicates that intestinal microbiota are
involved. Pulmonary methane excretion may serve as an indi-
cator of methane production by intestinal microbiota36. All
humans harbour methanogens in the colon, but methane
Table 5. Subject characteristics, urinary, microbial and dietary parameters in relation to the in vitro
8-prenylnaringenin (8-PN) producer phenotype, expressed as OR and upper and lower 95 % CI derived
from nominal logistic regression with poor in vitro 8-PN producers as reference category*
In vitro 8-PN producer
Moderate Strong
95 % CI 95 % CI
OR Upper Lower OR Upper Lower
Subject characteristics
Age (years) 1·117 0·986 1·265 1·104 0·938 1·300
BMI (kg/m2) 1·043 0·880 1·236 0·992 0·789 1·247
Smoking
Yes 2·265 0·100 51·41 0·000 0·000 0·000
No 1·000 Reference 1·000 Reference
Use of antibiotics
1– 3 months 1·171 0·041 33·52 0·000 0·000 0·000
3– 6 months 0·417 0·020 8·920 0·000 0·000 0·000
6– 12 months 2·872 0·311 26·55 2·646 0·177 39·50
$ 1 year 1·000 Reference 1·000 Reference
Urinary parameters
Urinary excretion (mg/d)
IX 1·000 0·996 1·004 0·993 0·982 1·004
8-PN 0·965 0·926 1·006 0·978 0·930 1·027
IX 0·985 0·874 1·109 1·165 0·980 1·384
Urinary recovery (%)
IX 0·950 0·465 1·943 0·882 0·334 2·330
8-PN 0·900 0·789 1·027 0·943 0·820 1·086
X 0·272 0·000 199·0 689·0 0·269 1·7 E6
Microbial parameters
Pulmonary methane excretion 0·771 0·287 2·071 0·599 0·143 2·502
Enzyme activities (mmol/h per g)
b-glucuronidase 1·015 0·948 1·087 1·023 0·931 1·123
b-glucosidase 0·999 0·965 1·034 0·999 0·943 1·058
Dietary parameters
Fat consumption (g/d)
Total fat 1·224 0·473 3·163 0·224 0·036 1·412
SFA 0·820 0·279 2·410 6·392 0·821 49·76
Unsaturated fatty acids 0·604 0·200 1·821 4·485 0·847 23·74
MUFA 1·583 0·600 4·180 0·901 0·341 2·381
PUFA 0·644 0·329 1·264 1·092 0·643 1·853
Fat consumption (%)
SFA 0·956 0·593 1·539 2·088 0·919 4·746
Unsaturated fatty acids 0·921 0·659 1·350 1·732 0·882 3·402
Fibre consumption (g/d) 1·025 0·927 1·132 1·065 0·940 1·208
Fat:fibre ratio 1·045 0·656 1·665 1·170 0·674 2·033
Alcohol consumption (g/d) 0·893 0·396 2·014 0·152 0·021 1·092
Methylxanthine intake (mg/d)
Caffeine 1·002 0·995 1·009 0·991 0·980 1·003
Theobromine 0·923 0·479 1·779 1·450 0·552 3·811
Pre-, pro-, synbiotics
$ once per week 0·425 0·042 4·352 2·125 0·283 15·97
once per week 0·000 0·000 0·000 0·000 0·000 0·000
2–3 times per month 0·000 0·000 0·000 0·000 0·000 0·000
once per month 0·243 0·026 2·272 0·000 0·000 0·000
# once per month 1·000 Reference 1·000 Reference
* For details of subjects and procedures, see Materials and methods.
IX, isoxanthohumol; X, xanthohumol.
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only appears in the breath if the concentration of Methanobre-
vibacter smithii exceeds 108/g dry weight faeces37. Age-
related increases in transit time and carbohydrate
malabsorption promote methanogenesis38 and may explain
the high prevalence of methane producers in the present
study. H2 gas is formed in the colon by a variety of hydrolytic
and saccharolytic bacteria to dispose reducing equivalents
during fermentation39 and is consumed by methanogenic,
homoacetogenic and sulphate-reducing microbiota. Compari-
son of the prevalence of the different H2-consuming micro-
biota in faecal samples of poor, moderate and strong 8-PN
producers will unravel the relationship between pulmonary
methane excretion and 8-PN production.
Several observational studies have reported differences in
dietary intake, particularly fat and fibre, in relation to equol
and enterolignan production capacities5,6,17,19. The present
study did not reveal significant differences. To our knowledge,
the effects of alcohol, caffeine, and theobromine consumption
on the gut microbiota and, hence, their phyto-oestrogen
metabolism have not been investigated directly. As these com-
pounds are rapidly and almost completely absorbed in the
stomach and the small intestine, they are not expected to
importantly affect the intestinal bacteria, although caffeine
intake has been associated with the microbial metabolism of
daidzein25,40. There is some suggestive evidence for an inhibi-
tory effect of alcohol on the activity of CYP1A241,42, the
mammalian enzyme system that has been shown to demethy-
late IX into 8-PN in vitro12. Thus, the involvement of hepatic
enzymes in the bioactivation of IX as suggested by Schaefer
et al.16 may explain why a lower reported alcohol consump-
tion was associated with the likelihood of being a strong
in vivo 8-PN producer. CYP1A2 activity accounts for almost
95% of the demethylation of caffeine43, but contributes only
partially to the elimination of theobromine44. Although low
and high caffeine consumers were equally present in the
current study population, intake of this CYP1A2 inducer
could not be linked to 8-PN production. The mechanism of
the positive correlation between theobromine consumption
and the strong 8-PN producer phenotype remains unclear.
As a constituent of cacao, theobromine is consumed by a
large proportion of the population, but it possesses little phar-
macological activity. It is important to note that only 10% of
the study population had a daily fibre intake above 30 g, as
recommended for seniors by the Belgian Health Council24.
As a consequence, the effect of fibre consumption or the fat:
fibre ratio on the conversion of IX into 8-PN may have been
overlooked in this study. Similarly, the influence of the
well-known induction of CYP1A2 activity by tobacco smok-
ing could not be clarified, as only four participants (8%)
were smokers. Even though the present study was not specifi-
cally designed to address this question, it is unlikely that
prior consumption of hop-derived products influences the
ability to convert IX into 8-PN, since no differences in the
habitual intake of prenylflavonoids were found between
the different 8-PN producer phenotypes. Analogously, soya
intervention studies failed to stimulate equol production in
low equol producers45,46.
Cross-classification analyses for 8-PN producer phenotype
estimated from in vivo and in vitro data indicated that
12·2% of the women were misclassified, while 53·1% were
classified correctly. This shows that the in vitro incubation
experiments give a good indication of the 8-PN producer phe-
notype and, additionally, stresses the important contribution of
the intestinal microbiota towards the in vivo bioactivation
of IX. Although the in vivo bioavailability is the final result
of intestinal absorption, human and microbial metabolism,
cellular retention, distribution and excretion, these results
show the potential of faecal incubations as an appropriate
screening assay.
Although biotransformation is generally regarded as a pro-
cess of metabolic inactivation prior to excretion, there are
many well-known examples of metabolic activation.
Demethylation by cytochrome P450 enzymes or by gut micro-
biota represents a common metabolic pathway for activation
of pro-oestrogens, such as the isoflavone formononetin47,48
and the synthetic steroid mestranol49. Similarly, in vivo
O-demethylation of IX into 8-PN increased the oestrogenic
potency of the hop-derived food supplements in this study,
since inter-individual differences in daily excretion of more
than 200mg 8-PN or 2–20mg 17b-oestradiol equivalents50
were observed.
In summary, we showed that individuals can be phenotyped
as poor (60%), moderate (25%) or strong (15%) 8-PN produ-
cers based on either urinary excretion data or faecal incubation
experiments. This inter-individual variation in 8-PN pro-
duction could be linked to differences in microbial and dietary
factors. From this study, we conclude that the oestrogenic
potency of hop-derived products depends on the 8-PN produ-
cer phenotype and the concentration of IX.
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